Acclaro Medical Secures $23 Million Funding to Advance Innovative Laser Technology
SMITHFIELD, R.I., May 29, 2025 – Acclaro Medical, a pioneering medical technology company, has successfully completed its Series B funding round, securing $23 million in investment. The funding was led by Accelmed Partners with participation from existing investor 3E Bioventures Capital.
This significant investment marks a major milestone for Acclaro Medical as it continues to develop cutting-edge solutions that improve patient care and redefine medical practices. The company’s flagship products, UltraClear® and AuraLux™, are set to benefit from this capital infusion, which will accelerate their growth and global market expansion. Additionally, the funding will advance the development of new products in Acclaro’s pipeline, further solidifying its position in the aesthetic industry.
Acclaro Medical’s UltraClear fiber laser has been recognized by leading aesthetic professionals as a breakthrough in Total Skin Health. This innovative 2910 nm cold ablative fiber laser, powered by proprietary 3DIntelliPulse™ technology, offers unparalleled clinical efficacy, superior patient experiences, and unmatched versatility. It is particularly notable for its significantly improved safety features for all skin types, including previously high-risk skin-of-color patients.
“Securing this Series B investment is a powerful testament to our team’s progress and potential,” said Helen Fang, CEO and Co-founder of Acclaro Medical. “This funding empowers us to continue our strong growth trajectory and realize our vision of improving the quality of life for people of all skin colors and ages worldwide.”
Shlomo Assa, President and co-founder of Acclaro Medical, added, “We are thrilled to have Accelmed’s support as we expand our global footprint. This investment is a strong vote of confidence in our mission to bring UltraClear and AuraLux to more individuals seeking anti-aging solutions for healthier, younger-looking skin.”
The Series B funding will enable Acclaro Medical to leverage Accelmed’s operational and financial expertise, alongside 3E Bioventures’ disciplined efficiency. This support will be instrumental in executing Acclaro’s strategic plans and cementing its position as a leader in innovative, patient-centered skin health solutions.
“Acclaro’s unique cold laser fiber technology is a game-changer in laser aesthetics,” stated Daniel Cohen, Accelmed’s venture partner. “It allows aesthetic practices to safely treat all skin types for major indications using a single device.”
With its commitment to innovation and team of dedicated professionals, Acclaro Medical continues to push boundaries and drive positive change in the aesthetic medical industry. The company’s proprietary technologies, including 3DMIRACL™ and Laser Coring™ skin rejuvenation treatments, are valued for their unrivaled aesthetic results, high patient comfort, rapid healing, and utmost safety across all skin types.
